EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 768 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Take a Small Step April 21, 2021 FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer October 15, 2024 Hormone Therapy for Prostate Cancer? A Genetic Test Could Help Decide March 15, 2021 Findings from a Population-Based Study on Cancers Associated with Alcohol Consumption July 28, 2021 Load more HOT NEWS ER-Low Positive Breast Cancer Shows Similar Clinical Behaviour and Response to... Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance... EMA Recommends Extension of Therapeutic Indications for Daratumumab 5-Year-Old Boy Battling Cancer Receives Dream Come True, Sworn In As...
